IOA-360 / iOnctura - LARVOL DELTA

Preclinical Activity of Novel TGF Beta Receptor I Kinase Inhibitors IOA-359 and IOA-360 for Treatment of Anemia in MDS/AML (ASH 2023) - "Furthermore, in selected samples, addition of Luspatercept led to greater maturation of erythrocytes. Our current results support the preclinical in vitro efficacy of ALK5 inhibitors IOA-359 and IOA-360 alone and in combination with Luspartercept, highlighting their potential for further development and clinical testing in MDS/AML."

Preclinical • Acute Myelogenous Leukemia • Anemia • Aplastic Anemia • Hematological Disorders • Myelodysplastic Syndrome • CD34 • GYPA • SMAD2 • TFRC • TGFB1 • TGFBR1

Transforming growth factor beta receptor type I (TGF-βRI) kinase inhibitors IOA-359 and IOA-360 stimulate erythropoiesis in MDS. (PubMed, Leuk Lymphoma) - "ALK5 inhibitors abrogated the growth inhibitory effects of TGF-β on healthy hematopoietic stem cells and stimulated hematopoietic differentiation in cell lines and MDS/AML specimens. These data demonstrate preclinical efficacy of two novel ALK5 inhibitors, IOA-359 and IOA-360, in stimulating erythroid differentiation in MDS and AML."

Journal • Acute Myelogenous Leukemia • Hematological Disorders • Hematological Malignancies • Leukemia • Myelodysplastic Syndrome • Oncology • TGFB1 • TGFBR1

iOnctura to present research on roginolisib and IOA-359 at ASH (PRNewswire) - "iOnctura...announces abstract data to be presented at the 65th American Society of Hematology (ASH) Annual Meeting and Exposition, San Diego, California, from 9-12 December 2023...'We are excited to present new research for roginolisib and IOA-359 at ASH. These data highlight the progress we are continuing to make in characterising and targeting resistance mechanisms across a variety of malignancies....at ASH we will present data on the role of TGF-b inhibition in myeloproliferative disorders. Building on our ongoing clinical investigation of roginolisib in patients with lymphoma, we will also present evidence of the synergy between Bcl-2 and PI3Kδ inhibition in Chronic Lymphocytic Leukemia (CLL).'"

Preclinical • Acute Myelogenous Leukemia • Chronic Lymphocytic Leukemia • Follicular Lymphoma • Myeloproliferative Neoplasm